FDA Approves Aliqopa (copanlisib) for Adults with Relapsed Follicular Lymphoma

September 14, 2017 -- The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news